Hypoparathyroidism: Integrating New Guidelines and Treatment Approaches

Sunday, April 2, 2017
7:00 – 9:30 pm
Hyatt Regency Orlando Ballroom R 
This educational activity is supported by an independent medical educational grant from Shire.



Target Audience

This continuing medical education activity should be of substantial interest to the community of endocrinologists, internists, surgeons, basic scientists, and other healthcare professionals who are committed to learning about the latest advances in endocrinology research and applying new findings to the evidence-based care of patients with hormone disorders.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:
  • Summarize the prevalence and most recent concepts of disease burden of hypoparathyroidism
  •  Summarize guidelines on conventional hypoparathyroidism management, which includes calcium, active and parent forms of vitamin D, and thiazide diuretics
  • Assess the efficacy and safety of PTH replacement therapy and indications for its use
  • Review data with regard to the effects of PTH replacement therapy on quality of life and non-skeletal features of hypoparathyroidism

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Bone and Calciotropic Hormones
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Level 6 (Patient Health)
Activity summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation
Course opens: 
Course expires: 

Program Director

John Bilezikian, MD
Dorothy L. and Daniel H. Silberberg Professor of Medicine
Professor of Pharmacology
Vice‐Chair, International Education and Research
Chief, Emeritus, Division of Endocrinology, Department of Medicine
College of Physicians and Surgeons
Columbia University
New York, NY
Bart L. Clarke, MD
Professor of Medicine
Mayo Clinic College of Medicine
Rochester, MN
Michael Mannstadt, MD
Chief, Endocrine Unit
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Dolores Shoback, MD
Professor of Medicine
University of California San Francisco
Staff Physician, San Francisco VA Medical Center
San Francisco, CA


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

John Bilezikian, MD: Advisory Group Member, Amgen, Shire; Ad Hoc Consultant, Lilly USA LLC

Bart L. Clarke, MD: Investigator, Shire; Advisory Group Member, Shire

Michael Mannstadt, MD: Advisory Group Member, Shire

Dolores Shoback, MD: Ad Hoc Consultant, Ascendis, Shire 

The following SPC member who planned and/or reviewed content for this activity reported financial relationships: Natalie Cusano, MD: Research Support, Shire; Speaker, Shire

The following SPC member who planned and/or reviewed content for this activity reported no relevant financial relationships: Amy Rothberg, MD

The following SPC Committee members reported financial relationships:

Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi

Andrew Ahmann, MD: Research Support, DexCom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexco, Novo Nordisk, Trividia Health

Giuseppe Barbesino, MD: Spouse, employee of Genzyme

John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals

Joan Han, MD: Research Support, Rhythm Pharmaceutical

Alan Kelly, MD: Speaker, Eli Lilly

E Michael Lewiecki, MD: Consultant, Amgen, Merck, Eli Lilly, Radius Health, Shire, Abbvie and Alexion; Speaker, Alexion, Shire; Research Grant Support, Amgen, Eli Lilly, Merck

Lisa Nachtigall, MD: Consultant, Ipsen, Novartis, Corcept; Grant Support/Investigator, Chiasma

Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships: Connie Newman, MD 


Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation